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Xiangjun Chen1,2, Aleksandar Stojanovic1,2,3* , Jon Roger Eidet4 and Tor Paaske Utheim4,5Abstract
Corneal collagen cross-linking (CXL) is a therapeutic procedure aiming at increasing the corneal stiffness in
the keratoconus eyes by induction of cross-links within the extracellular matrix. It is achieved by ultraviolet-A
(370 nm) irradiation of the cornea after saturation with the photosensitizer riboflavin. In the conventional CXL
protocol, a minimum de-epithelialized corneal thickness of 400 μm is recommended to avoid potential irradiation
damage to the corneal endothelium. In advanced keratoconus, however, stromal thickness is often lower than
400 μm, which limits the application of CXL in that category. Efforts have been undertaken to modify the
conventional CXL procedure to be applicable in thin corneas. The current review discusses different techniques
employed to achieve this end and their results. The overall safety and efficacy of the modified CXL protocols
are good, as most of them managed to halt the progression of keratectasia without postoperative complications.
However, the evidence of safety and efficacy in the use of modified CXL protocols is still limited to few studies
with few patients involved. Controlled studies with long-term follow-up are required to confirm the safety and
efficacy of the modified protocols.
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Keratoconus is a degenerative disorder of the cornea, char-
acterized by progressive stromal thinning and conical ecta-
sia that result in irregular astigmatism and associated vision
loss [1, 2]. It was estimated that the stiffness of a keratoco-
nic cornea is only 60 % of that of the normal cornea, and
that the development of conical shape in keratoconus is the
result of decreased biomechanical stability [3]. The patho-
genesis of keratoconus on molecular level is still uncertain,
although it mainly seems to be caused by a reduced num-
ber of collagen cross-links and higher pepsin digestion than
in normal corneas [3–5]. Reduced mean diameter and
interfibrillar spacing of the collagen fibrils [6], slippage of
collagen lamellae [7, 8], as well as a loss of the normal inter-
woven structure of the lamellae [9], have been reported.
Until the introduction of corneal collagen cross-linking
(CXL), therapeutic solutions for keratoconus have been
limited to the treatment of the consequences of progressive
weakening of the cornea – from rigid gas permeable* Correspondence: aleks@online.no
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article, unless otherwise stated.contact lenses (RGP) to corneal transplantation (deep an-
terior lamellar or penetrating keratoplasty) ultimately [10].
RGP alleviates the symptoms, but does not address the
basic defect within the keratoconic cornea, thus the colla-
gen weakening will be unaffected and still continue to
progress [10]. Keratoconus remains among the leading in-
dications for penetrating keratoplasty [11], which is a
major ophthalmic surgical procedure involving risk for re-
jection and other serious complications. The 10-year graft
survival after penetrating keratoplasty for keratoconus was
reported to be 89 % [12].
Corneal crosslinking with riboflavin/ultraviolet-A (UVA,
370 nm), introduced merely a decade ago, is a minimally
invasive procedure for treatment of keratectasia via increas-
ing the mechanical and biomechanical stability of the stro-
mal tissue [13–17]. The aim of CXL is to create new
chemical bonds (cross-links) between collagen fibrils and
other extracellular matrix proteins in the corneal stroma
through localized photo polymerization [18]. Exposure of
the riboflavin to UVA-irradiation results in absorption
of energy and its excitement into a triplet state that
undergoes either an aerobic, type 2 reaction, or an an-
aerobic, type 1 reaction [19]. According to Kamaev ande is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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of singlet molecular oxygen, which then acts on tissue to
produce additional cross-linked bonds. After a quick con-
sumption of oxygen, which occurs only within several sec-
onds, depending on UV-power, temperature, amongst
other factors, it is suggested that the main photochemical
kinetics mechanism is the direct interaction between the
riboflavin triplets and reactive groups of corneal proteins,
which leads to the cross-linking of the proteins mainly
through radical reactions [19]. These then induce forma-
tion of new covalent bonds between the amino acids
among the neighboring collagen molecules [17, 20] and
among proteoglycan (PG) core proteins, as well as limited
linkages between collagen and PG core proteins [21].
The riboflavin also offers a shielding effect to the deeper
ocular structures, such as the corneal endothelium, lens,
and retina [22], by absorbing the UVA [13, 22]. The crit-
ical limitation of CXL in thin corneas is the lack of suffi-
cient corneal thickness for the UVA-radiation to be
absorbed and attenuated before it reaches the endothe-
lium. The cell damage threshold of UVA-irradiation
combined with riboflavin is 10 times higher than with
UVA-irradiation alone [23]. Wollensak et al. [23] dem-
onstrated that when the combination of UVA and ribo-
flavin is used in corneas thinner than 400 μm, theTable 1 Safety of CXL in thin corneas
Author, year No. of
eyes
Surgical procedures Follow up
(months)
VA and t
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Jacob, et al. 2014 [73] 14 Contact lens-
assisted
6–7 CDVA st
Kmax = Maximum keratometric reading, Kmin = Minimum keratometric reading, Kmea
acuity, UDVA = Uncorrected distance visual acuity, CDVA = Corrected distance visuacytotoxicity threshold of 0.35 mW/cm2 for the endo-
thelial cell damage can be reached. In conventional
CXL procedure, the treatment parameters (0.1 % ribo-
flavin in dextran 20.0 % solution and 3 mW/cm2 of
UVA for 30 minutes) are assumed to treat the anterior
300 μm of the corneal stroma [24, 25]. Hence, only the
patients with a de-epithelialized corneal thickness of at
least 400 μm are subjected to this treatment. The
downside of this limitation is that eyes with advanced
stages of keratectasia often have corneas thinner than
400 μm. Populations of Asian and African origin with
inherently thinner corneas [26, 27] may be especially
affected by this limitation. Various modifications have
been suggested to circumvent that [28–31]. The current
review discusses the variety of CXL treatment protocols in
thin corneas, as well as their efficacy and safety published
in peer-reviewed literature. The results of different CXL
protocols in treatment of keratectasia in thin corneas are
listed in Table 1.
Review
Conventional collagen cross-linking
The conventional CXL procedure as described in the Dres-
den protocol in 2003 [17], its modified version in 2008 [32],




d CDVA improved, Kmean reduced Yes No
le or reduced – No
d Kmax stable – No
st 1 line CDVA, the rest remained stable or
d, Kmax and Kmin reduced
No No
proved, Kmax, Kmin and Kmean remain stable No No
able, Kmax stable Yes No
d CDVA improved, keratometry values
d
No No
d CDVA improved, Kmax reduced No No
phy stable No No
– No
DVA stable, Kmean reduced No No
able, Kmax stable No No
n = Mean keratometry reading, SimK = Simulated keratometry, VA = Visual
l acuity
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the central 7–9 mm of corneal epithelium followed by instil-
lation of isoosmolar riboflavin 0.1 % solution in 20 % dex-
tran. UVA (370 nm) irradiation with 3 mW/cm2 of UVA for
30 minutes (5.4 J/cm2) over 8 mm diameter of central cor-
nea is initiated after stromal saturation with riboflavin. The
efficacy of this protocol is supported by numerous studies
since its introduction in 2003 [17, 34–37].
Kymionis et al. [38] applied conventional CXL pro-
cedure in 14 thin corneas with minimum corneal thick-
ness of less than 400 μm (range 340–399 μm) after
epithelial removal. Improvement in uncorrected dis-
tance visual acuity (UDVA), corrected distance visual
acuity (CDVA), and reduction in mean keratometry
readings were recorded during the 12 months follow-
up. However, despite the absence of clinically evident
complications, significant reduction of endothelial cell
density from 2733 to 2411 cells/mm2 was observed
postoperatively. The film of 0.1 % isoosmolar riboflavin
with 20 % dextran was measured to be approximately
70 μm thick after 1 minute of instillation and remained
stable for 22 minutes [39]. With the riboflavin-dextran
film, the UVA irradiance in human corneal stroma at
400 μm was measured to be 0.21 mW/cm2, which is
much lower than the previously mentioned cytotoxicity
level on which the set limitation of minimal deepithelia-
lized stromal thickness of 400 μm is based. Hence, the
absorption and shielding of UVA by the riboflavin film
may have prevented the damage to the endothelium.
Nevertheless, longer follow-up and larger patient series is
essential to evaluate the safety and efficacy of conventional
CXL in clinical application in thin corneas.
Hypoosmolar riboflavin solution
The cornea has an inert swelling pressure [40], meaning
that the corneal stroma has the tendency to increase its
volume in an isooncotic environment. The deepithelia-
lized cornea can swell to double its normal thickness
when irrigated with a hypoosmolar solution [41]. Hafezi
and co-workers [30] applied this method to increase cor-
neal thickness before CXL in thin corneas. After epithe-
lial removal, 0.1–20 % dextran isoosmolar riboflavin was
applied to the cornea for 30 minutes. The 0.1 % dextran-
free hypoosmolar riboflavin was then administered until
the corneal thickness at the thinnest point reached
400 μm, before the initiation of UVA irradiation. The
authors reported a stabilization of keratectasia in 20 eyes
treated with this approach. A later study by Raiskup
et al. [42] applied 0.1 % hypoosmolar riboflavin after epi-
thelial debridement until the riboflavin saturated cornea
reached the minimum of 400 μm. In this study, one year
after the treatment, CDVA and keratometric value
remained unchanged and no damage to the cornea in
the form of detectable scarring lesions in the stromawas registered. Similar results were reported by Wu et al.
[43] On the contrary, in eyes treated with isoosmolar ribo-
flavin solution, a permanent stromal scar tended to de-
velop in thin corneas after CXL [44]. Gu et al. [45] used
0.1 % hypoosmolar riboflavin solution as saturation and
swelling solution in 8 thin corneas that underwent CXL
procedure. They reported a slight decrease of endothe-
lial cell density 3 months after the treatment.
The preoperative swelling of the cornea broadens the
spectrum of CXL indications to thinner corneas. How-
ever, Hafezi and colleagues [46] reported a case where
CXL could not stop the progression of keratoconus in a
very thin cornea (minimal thickness of 268 μm after
removal of the epithelium), despite the fact that swell-
ing with hypoosmolar riboflavin solution increased the
thickness to 406 μm and no adverse endothelial reac-
tion was observed postoperatively. The authors, there-
fore, hypothesized that there is a minimal, yet to be
determined stromal thickness necessary for effective
CXL to occur. They suggested a minimal stromal thick-
ness of 330 μm or more before swelling, when using
hypoosmolar riboflavin solution.
Kaya et al. [47] and Soeters et al. [48] performed
intraoperative corneal thickness measurements during
CXL with hypoosmolar riboflavin solution in thin cor-
neas. They found that the artificial swelling effect was
transient, and the thinnest pachymetric readings de-
creased significantly after 10 and 30 minutes of isoos-
molar riboflavin (with dextran) application, with or
without UVA irradiation. Thinning of deepithelialized
cornea after instillation of 0.1–20 % dextran riboflavin
isoosmolar solution has also been reported in other
studies [49, 50]. The authors inferred that the reduction
of the corneal thickness was induced by the hyperonco-
tic effect of the dextran. Vetter et al. [51] evaluated the
modulatory effect of various riboflavin 0.1 and 0.2 %
compositions on the central corneal thickness in fresh
postmortem porcine eyes. No correlation between the
osmolarity of the composition and the swelling behavior of
the treated corneas was observed, whereas an inverted cor-
relation was verified between the dextran concentration
and the swelling effect. Concurrently, lower absorption
and shielding effect of the thinner hypoosmolar ribofla-
vin film on the cornea, by application of the hypoosmo-
lar riboflavin without dextran alone, would increase
irradiance level in the stroma, putting the endothelium
at higher risk [39]. Therefore, the cornea should be
swollen to a thickness greater than 400 μm or concen-
tration of riboflavin in the hypoosmolar solution could
be increased. It was therefore suggested that develop-
ment of new riboflavin solutions with isooncotic prop-
erties to create a stable film could increase the safety of
CXL [50]. Moreover, lack of the evaporation resistance
provided by the corneal epithelium [52], and/or an increase
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thinning [53–55]. It was proposed that removal of the
lid speculum during riboflavin saturation, and use of
irradiating devices with shorter irradiation time (and
higher power) might be advantageous [47, 50, 54, 55].
Monitoring the corneal thickness throughout CXL
treatment could also be important. CXL can be ex-
pected to have less effect on biomechanics of artificially
swollen corneas due to the lower relative concentration
of collagen in the hydrated stroma [56, 57]. Long-term
follow-up studies addressing this issue are warranted.
Transepithelial collagen cross-linking
Substances such as benzalkonium chloride, ethylenedi-
aminetetraacetic acid (EDTA) and trometamol, especially
when combined, enhance epithelial permeability of hydro-
philic macromolecules, such as riboflavin [58–61]. By add-
ing the enhancers to help riboflavin penetrate to the
corneal stroma through the intact epithelium, CXL can be
performed without epithelial debridement (transepithelial
CXL) [28]. Transepithelial CXL has been proposed (but
not proven) to reduce early postoperative pain, temporary
worsening of vision, as well as complications such as
infectious keratitis after conventional CXL [62]. Addition-
ally, thinner corneas may be treated safer by transe-
pithelial compared to the conventional CXL, since the
endothelium is better protected by UVA-filtering effect
of the intact epithelium.
In a bilateral study, Filippello et al. used trometamol
and sodium EDTA as enhancers and applied transepithe-
lial CXL in 20 keratectatic eyes with a mean corneal
thickness (including epithelium) of 412 ± 21 μm [28].
The transepithelial CXL treatment appeared to halt the
progression of keratoconus in all treated eyes over
18 months follow-up. It also yielded statistically signifi-
cant improvements in all visual and topographic out-
come measures, whereas the contralateral untreated eyes
demonstrated worsening of all parameters. Spadea et al.
[31], who used a similar protocol in thin corneas, con-
firmed its effect in stabilization of the keratoconic eyes.
However, the visual and topographic improvement was
minimal. No endothelial cell damage was observed in
either of the studies.
Wollensak et al. estimated a 64 % increase in corneal
rigidity in human corneas with transepithelial CXL
using topical anesthetics and benzalkonium chloride as
enhancers, versus a 320 % increase when using CXL
with de-epithelialization [63]. The safety and reproduci-
bility of the study by Filippello et al. have recently been
questioned [64] since the postoperative demarcation
line depth in their study [28] was only approximately
100 μm, in contrast to about 300 μm in conventional
CXL with epithelial debridement. Seiler and Hafezi [24]
first reported the demarcation line after CXL andrelated the depth of the line to that of keratocyte death
after CXL as measured by confocal microscopy [65].
They suggested that the line represented the transition
zone between cross-linked anterior and untreated pos-
terior stroma. It is unclear whether the shallower de-
marcation line using the transepithelial approach was
due to limited penetration of riboflavin into the stroma
or that it was a result of reduced UVA-light penetration
by shielding from riboflavin-impregnated intact corneal
epithelium. Iontophoresis-assisted transepithelial CXL,
using a noninvasive delivery system based on a small
electric current, was recently designed to enhance the
penetration of riboflavin into the corneal stroma [66].
Preclinical results showed that the iontophoresis was able
to increase the concentration of riboflavin in the corneal
stroma when compared to enhancer-assisted transepithe-
lial CXL, but did not reach concentrations previously
reached with conventional epithelium-off CXL. Demarca-
tion line after iontophoresis-assisted transepithelial CXL
appeared to be less easily distinguishable and shallower
than in conventional CXL, however, it demonstrated
features more similar to that after conventional CXL in
terms of depth and visualization, compared to enhancer-
assisted transepithelial CXL [63, 67]. In general, there is
consensus within the scientific community that current
transepithelial CXL protocols are not as effective as con-
ventional epithelium-off CXL [60, 61, 68].Custom epithelial debridement technique
Kymionis et al. [29] performed CXL with custom
pachymetry-guided epithelial debridement in one kerato-
conic eye and one post-LASIK keratectatic eye with thin-
nest stroma of less than 400 μm. In this modified CXL
approach, 8.0 mm diameter of corneal epithelium was re-
moved; leaving a small, localized area of corneal epithe-
lium corresponding to the thinnest area over the apex of
the cone. The authors suggested use of hypoosmolar ribo-
flavin during the UVA-irradiation to avoid corneal stromal
dehydration as well as to maintain the stromal riboflavin
concentration. Nine months postoperatively, topography
remained stable, and no endothelial cell density alteration
was detected in the treated eyes. However, a later study
by Kaya et al. [69] suggested that the epithelium over
the cone area spared the stroma underneath from the
CXL effect. Four weeks after the treatment, stromal
haze and demarcation line were detected in the corneal
areas with epithelial debridement, but not in the areas
with intact epithelium; deepithelialized stroma outside
the cone region displayed total keratocyte apoptosis
and honeycomb-like edema, whereas it was minimal be-
neath the intact epithelium [69]. In contrast, Mazzotta
et al. [70] demonstrated keratocyte apoptosis at an average
depth of 160 μm under the epithelial island compared to
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1-year follow-up.
One previous study demonstrated that the stromal
uptake of riboflavin after grid pattern of full-thickness
epithelial debridement was heterogeneous, with full
penetration to the stroma immediately beneath the
areas of epithelial debridement and no penetration to
the stroma beneath the intact epithelium [71]. Inad-
equate riboflavin saturation together with the ability of
the epithelium to absorb the UVA radiation [72] may
lead to reduced CXL effect in the cone area and affect
the efficacy of the whole procedure. Long-term efficacy
of this modified CXL procedure with a larger number
of patients needs to be assessed.
Contact lens-assisted collagen cross-linking
Contact lens-assisted CXL (CACXL) was introduced by
Jacob et al. [73] A Soflens daily disposable soft contact
lens (14 mm diameter, 8.6 mm basal curvature; Bausch
& Lomb) of 90 μm thickness made of hilafilcon and
without UV filter was immersed in isoosmolar riboflavin
0.1 % in dextran for 30 minutes, before it was applied
onto the deepithelialized, riboflavin-saturated cornea.
The UVA-radiation of 3.0 mW/cm2 for 30 minutes was
initiated after the confirmation that the minimum cor-
neal thickness including the contact lens and riboflavin
film was greater than 400 μm. The riboflavin solution
was instilled every 3 minutes during the UVA-radiation
to maintain corneal saturation and to keep the pre-
corneal and pre-contact lens riboflavin film uniform.
The pre-corneal riboflavin film with contact lens created
an absorption medium in the pre-corneal space by artifi-
cially increasing the thickness of the “riboflavin-filter”.
In the 14 eyes treated with CACXL, the authors re-
ported an average increase of the minimum corneal
thickness by 108 μm if the contact lens and riboflavin
film were included. At a mean follow-up time of 6.1 ±
0.3 months (range: 6–7 months), the mean postoperative
depth of the stromal demarcation line was measured at
252.9 μm. No significant endothelium loss or signs of
postoperative endothelial damage were observed. No
significant change in the CDVA, or mean maximum kera-
tometric value was detected postoperatively, although 1 D
decrease of maximum keratometric value was observed in
4 eyes (28.5 %).
The advantage of the CACXL is that it is not
dependent on the swelling properties of the cornea and
that the cornea is not subjected to edema, which may
cause Descemet membrane folds and endothelial dam-
age. However, the surface irradiance at the level of the
corneal stroma is reduced by 40–50 % in CACXL
secondary to absorption by the riboflavin film and
soaked contact lens. Furthermore, oxygen diffusion,
which has been demonstrated to be crucial in the CXLprocess, might be hindered by the contact lens. As a
result, the effect of CXL may be reduced. The small
patient population, short follow-up and absence of a
control group are the limitations of the study.Conclusion
A minimum corneal thickness of 400 μm is recommended
in conventional CXL treatment. With improved screening
technique in keratoconus diagnosis, most of the keratoco-
nus eyes would be able to be treated by this protocol.
However, late diagnosed progressive keratoconus eyes
often have values below this threshold. To offer CXL to
this critical group of patients, several modifications have
been proposed. The overall safety of the presented proto-
cols for CXL in thin corneas is good, as most of them
managed to halt the progression of keratectasia without
postoperative complications. Furthermore, modification of
the tonicity and concentration of the photosensitizing
riboflavin and modification of the UV energy and/or
power have been proposed. Iseli et al. [74] suggested that
a higher riboflavin concentration may be applied for im-
proved protective screening of the endothelium in thin
corneas. Accelerated CXL (UVA irradiation at 30 mW/
cm2 for 3 minutes) has recently been reported to stabilize
the progression of keratoconus in 34 thin corneas, without
endothelial cell density loss during the 12 months of
follow-up [75]. Furthermore, in accelerated CXL, pulsed
UV light seems to result in a higher effect compared to
continuous UV light, presumably due to optimization of
oxygen availability [76]. Oxygen concentrations measured
in the corneal stroma showed that the certain combin-
ation of “on” and “off” time would facilitate continuous re-
plenishment of oxygen [77], leading to increased CXL
effect without the necessity to increase UV energy [78].
Thus, using the pulsed mode during UVA irradiation may
maximize the efficacy of CXL while maintaining or im-
proving the safety profile of the procedure, which may be
especially beneficial in treating thin corneas.
Ideally, a comprehensive mathematical model should
be introduced to calculate an optimal set of parameters
such as concentration and tonicity of Riboflavin, as well
as UV-light-power, duration and dose for any given cor-
neal thickness. That way not only the limitation of the
treatment in thin corneas will be addressed, but a cus-
tomized set of parameters could lead to addressing
specific needs of any individual patient. At this point,
only laboratory research can be found on the subject
[79, 80].
The evidence of safety and efficacy regarding the use
of modified CXL protocols is still limited to a handful of
studies. Future long-term follow-up studies with a larger
number of participants are warranted.
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